She had a US postdoc offer sitting on the table.
A government fellowship. A predictable, prestigious career path.
She said no to all of it.
Not for a bigger opportunity.
For a smaller, harder one.
Meet Dr Parul Ganju.
A PhD in Skin Biology from NII, New Delhi.
During her doctoral research, she kept meeting people with vitiligo — the autoimmune condition that destroys pigment-producing cells and leaves white patches on the skin.
In India, where a mark on your skin can shape confidence, relationships, even careers, she saw something papers don't capture.
People were waiting for something to work.
That line never left her head.
Existing treatments for vitiligo?
Mostly steroids.
Millions of patients. Decades of medicine.
Still no drug that targets the actual root cause.
So in 2016, instead of writing another paper about the problem, she decided to build the fix.
Dr Ganju co-founded Ahammune Biosciences in Pune with her PhD collaborator Dr Krishnamurthy Natarajan.
No safety net. Just years of fundraising, failed experiments, and long trial timelines ahead.
The company's drug candidate, AB1001, took a different route entirely.
Instead of broadly shutting down the immune system, it targets the exact cellular pathway that kills melanocytes.
Her own words for it:
"Cutting fuel to the fire."
Fast forward to now.
Real progress. Not just a pitch deck.
Today is World Allergy Day — a day built around immune-related disorders.
Vitiligo isn't technically an allergy.
But it is the immune system attacking the body's own cells.
Same battlefield. Different disease.
Which makes her story land even harder today.
Every year, thousands of Indian graduates chase the same dream — a foreign fellowship, an international lab, a "settled" career.
Nothing wrong with that.
But Dr Ganju's choice shows there's another version of ambition.
One where staying back is the bold move.
India carries one of the world's largest vitiligo patient populations.
Whether AB1001 ultimately reaches patients still depends on trial results and regulatory approval.
But somewhere in Pune, a scientist who could've been publishing papers abroad is instead trying to give millions of people their skin — and their confidence — back.
That's all for now!
